Chronic HBV Infection outside Treatment Guidelines: Is Treatment Needed?

Abstract

Background

There are now seven antivirals approved for use in the management of chronic HBV infection in the US. Current professional guidelines recommend the use of antiviral treatment in only a distinct subset of the total HBV chronically infected population, estimated to be more than 350 million worldwide. The subset of chronically HBV-infected individuals for whom the antivirals have been demonstrated to produce desirable outcomes are those with abnormal liver enzymes and a viral load above a defined threshold, presumably identifying those at highest risk for development of cirrhosis and hepatocellular carcinoma. However, some individuals whose clinical features place them outside these guidelines, for whom treatment is not recommended, are also at significant risk for liver disease complications and liver-related death.

Methods

In this report, we produce new estimates of the age-specific risks of liver-related death in people outside the current treatment guidelines using published data from multiple populations.

Results

Our results indicate that the age-specific 10-year risks of liver-related mortality in these individuals range from 0.3–4% in the West to 0.3–20% in Asia.

Conclusions

The magnitude of these risks and the estimated size of the global population that falls outside of current treatment guidelines have led us to consider whether medical interventions are also needed for these individuals, either with currently approved therapeutics or yet-to-be-discovered medications targeting new mechanisms of antiviral effect. Potential targets for development of new medications are discussed.

References

Amin

, Law

M.G.

, Bartlett

, Kaldor

J.M.

, Dore

G.J.

Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938–945.

Chen

, Lin

W-Y

, Shen

F.M.

Chronic HBV infection and mortality for non-liver causes: results from the Haimen City Cohort Study. Int J Epidemiol 2005; 34: 132–137.

McMahon

B.J.

The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45–S55.

McMahon

B.J.

Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006; 101 Suppl 1: S7–S12.

Lok

A.S.

, Heathcote

E.J.

, Hoofnagle

J.H.

Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology 2001; 120: 1828–1853.

Beasley

R.P.

Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–1956.

Beasley

R.P.

Hepatitis B virus as the etiologic agent in hepatocellular carcinoma – epidemiologic considerations. Hepatology 1982; 2: 21S–26S.

Evans

A.A.

, Chen

, Ross

E.A.

Eight-year follow-up of the 90,000-person Haimen City Cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369–376.

Chen

C.J.

, Yang

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

10.

Ribes

, Cleries

, Rubio

Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006; 119: 687–694.

11.

Hepatitis B Foundation. HBF drug watch. (Updated 7 November 2012. Accessed 1 December 2012.) Available from http://www.hepb.org/professionals/hbf_drug_watch.htm.

12.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

13.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–662.

14.

Keeffe

E.B.

, Dieterich

D.T.

, Han

S.H.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315–1341.

15.

Keeffe

E.B.

, Dieterich

D.T.

, Han

S.H.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.

16.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.

17.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–283.

18.

Kwon

, Lok

A.S.

Does antiviral therapy prevent hepatocellular carcinoma?

Antivir Ther 2011; 16: 787–795.

19.

Tong

M.J.

, Pan

C.Q.

, Hann

H.W.

The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011; 56: 3143–3162.

20.

Tong

M.J.

, Hsu

, Chang

P.W.

, Blatt

L.M.

Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. J Gastroenterol Hepatol 2011; 26: 829–835.

21.

Chen

, Lin

, Shen

Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797–1803.

22.

Liaw

Y-F

, Sung

J.J.Y.

, Chow

W.C.

Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–1531.

23.

Yuen

M.F.

, Seto

W.K.

, Chow

D.H.

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12: 1295–1303.

24.

Cohen

, Holmberg

S.D.

, McMahon

B.J.

Is chronic hepatitis B being undertreated in the United States?

J Viral Hepat 2011; 18: 377–383.

25.

Gish

R.G.

, Gadano

A.C.

Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006; 13: 787–798.

26.

Tai

D.I.

, Lin

S.M.

, Sheen

I.S.

Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009; 49: 1859–1867.

27.

Tong

M.J.

, Sun

H.E.

, Hsien

, Lu

D.S.

Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci 2010; 55: 826–835.

28.

Tong

M.J.

, Nguyen

M.O.

, Tong

L.T.

, Blatt

L.M.

Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2009; 7: 889–893.

29.

Villa

, Fattovich

, Mauro

, Pasino

Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Dig Liver Dis 2011; 43 Suppl 1: S8–S14.

30.

Yang

H.I.

, Sherman

, Su

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28: 2437–2444.

31.

Crook

P.D.

, Jones

M.E.

, Hall

A.J.

Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003; 32: 118–124.

32.

Villeneuve

J.P.

, Desrochers

, Infante-Rivard

A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 1000–1005.

33.

Manno

, Camma

, Schepis

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756–763.

34.

Brunetto

M.R.

, Oliveri

, Coco

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–270.

35.

Niederau

, Heintges

, Lange

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–1427.

36.

Papatheodoridis

G.V.

, Manesis

, Hadziyannis

S.J.

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306–313.

37.

Mazzella

, Saracco

, Festi

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94: 2246–2250.

38.

Fattovich

, Olivari

, Pasino

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84–90.

39.

Fattovich

, Bortolotti

, Donato

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–352.

40.

Prati

, Taioli

, Zanella

Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1–10.

41.

Kim

H.C.

, Nam

C.M.

, Jee

S.H.

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.

42.

Eckman

M.H.

, Kaiser

T.E.

, Sherman

K.E.

The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011; 52: 1294–1306.

43.

Tong

M.J.

, Hsien

, Hsu

, Sun

H.E.

, Blatt

L.M.

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070–1078.

44.

Manos

M.M.

, Leyden

W.A.

, Murphy

R.C.

, Terrault

N.A.

, Bell

B.P.

Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology 2008; 47: 1150–1157.

45.

, Kochanek

M.A.

, Murphy

S.L.

, Tejada-Vera

National vital statistics reports. Deaths: final data for 2007. Hyattsville, MD: National Center for Health Statistics 2010; pp. 1–135.

46.

World Health Organization. Causes of death summary tables. (Updated May 2011. Accessed 1 May 2012.) Available from http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.

47.

Adams

L.A.

, Lymp

J.F.

, St Sauver

The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113–121.

48.

Ekstedt

, Franzen

L.E.

, Mathiesen

U.L.

Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–873.

49.

Bhala

, Angulo

, van der Poorten

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208–1216.

50.

Artz

A.S.

, Somerfield

M.R.

, Feld

J.J.

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28: 3199–3202.

51.

Loomba

, Rowley

, Wesley

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519–528.

52.

Chan

A.C.

, Chok

K.S.

, Yuen

W.K.

Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011; 146: 675–681.

53.

Hann

H.W.

, Bergin

, Coben

, DiMarino

A.J.

Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. Int J Cancer 2011; 128: 739–742.

54.

Lok

A.S.

, Wu

P.C.

, Lai

C.L.

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091–2097.

55.

Lai

C.L.

, Lok

, Lin

Placebo-controlled trial of recombinant a₂-interferon in Chinese HBsAg-carrier children. Lancet 1987; 2: 877–880.

56.

Lai

C.L.

, Lin

H.J.

, Lau

J.N.

Effect of recombinant alpha 2 interferon with or without prednisone inChinese HBsAg carrier children. Q J Med 1991; 78: 155–163.

57.

Lok

A.S.

Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?

J Gastroenterol Hepatol 2011; 26: 221–227.